Compare Illumina, Inc. (ILMN) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs L3Harris Technologies Inc — how do they compare? Illumina, Inc. trades at $275.1 (market cap $39.95B), while L3Harris Technologies Inc trades at $236.69 (market cap $44.12B). The key difference: Illumina, Inc. and L3Harris Technologies Inc are close in size by market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and L3Harris Technologies Inc for 56 Days on average.
| ILMN | LHX | |
|---|---|---|
Market Cap | $39.95B | $44.12B |
Volume | 3,169,503 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $293.69 | $378.48 |
52-Week Low | $91.00 | $233.63 |
Typical Hold Time | 83 Days | 56 Days |
Enterprise Value | $41.31B | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
LHX trades at $237.15, up 1.51% on the day, with a bearish technical signal from moving averages but strong fundamental performance, including three consecutive quarterly EPS beats. The company secured major defense contracts totaling over $10.7 billion in September 2026, supporting future revenue growth. Profit margins have improved steadily, with net income margin reaching 7.34% in 2025, and cash flow from operations strengthened to $3.11 billion.
The outlook is positive given robust contract wins and earnings momentum, but risks include ongoing legal investigations and high debt levels. Analyst consensus is strongly bullish with a $340 price target, implying significant upside from current levels, though technical indicators suggest near-term resistance around $238-$240.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
